← Leaderboards
Davide Ruggero
University Of California, San Francisco
$27,506,499
Attributed
$31,753,272
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,753,272 · 13
By mechanism
R01$24,285,556 · 10
R35$6,439,669 · 1
P50$1,016,152 · 1
P41$11,895 · 1
Top collaborators
- William A Weiss10 shared
- Jonathan D. Dinman5 shared
Others in their field
Top investigators on “Translations”
- Lee Marshall Nadler · Dana-Farber Cancer Inst$375,212,111
- Leonard Freedman · Leidos Biomedical Research, Inc.$362,430,297
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$293,499,096
- Steven E Reis · University Of Pittsburgh At Pittsburgh$281,789,183
- David Heimbrook · Leidos Biomedical Research, Inc.$265,645,121
- Gregory H Reaman · National Childhood Cancer Foundation$259,780,965
Research focus
TranslationsMalignant NeoplasmsMolecularGeneticTumorOncogenicMediatingMouse ModelMessenger RnaIn VivoCellsGene ExpressionProtein BiosynthesisProteinsRibosomesPathway InteractionsSignal TransductionUntranslated RegionsProgramsNovel TherapeuticsInsightAffectCancer CellBase
Grant awards (63)
Translational control underlies nutrition and metabolism in health and disease$2,971,227
R01 · FY2025 · DK · contact PI
Mechanisms of regulated translation control in cancer and its therapeutic implications$968,984
R35 · FY2025 · CA · contact PI
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications$666,183
R01 · FY2025 · NS
Project 3 - Deciphering the Role of the Translational Oncogenic Program in Prostate Cance$504,472
P50 · FY2025 · CA · contact PI
ERa is a novel RNA-binding protein controlling breast cancer$468,008
R01 · FY2025 · CA · contact PI
Mechanisms of regulated translation control in cancer and its therapeutic implications$920,535
R35 · FY2024 · CA · contact PI
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications$646,197
R01 · FY2024 · NS
Project 3 - Deciphering the Role of the Translational Oncogenic Program in Prostate Cance$511,680
P50 · FY2024 · CA · contact PI
ERa is a novel RNA-binding protein controlling breast cancer$448,158
R01 · FY2024 · CA · contact PI
Mechanisms of regulated translation control in cancer and its therapeutic implications$949,604
R35 · FY2023 · CA · contact PI
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications$666,183
R01 · FY2023 · NS
ERa is a novel RNA-binding protein controlling breast cancer$468,839
R01 · FY2023 · CA · contact PI
Mechanisms of regulated translation control in cancer and its therapeutic implications$949,604
R35 · FY2022 · CA · contact PI
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications$666,183
R01 · FY2022 · NS
ERa is a novel RNA-binding protein controlling breast cancer$478,371
R01 · FY2022 · CA · contact PI
Mechanisms of regulated translation control in cancer and its therapeutic implications$968,984
R35 · FY2021 · CA · contact PI
Mechanisms of regulated translation control in cancer and its therapeutic implications$968,984
R35 · FY2020 · CA · contact PI
Mechanisms of regulated translation control in cancer and its therapeutic implications$712,974
R35 · FY2019 · CA · contact PI
Delineating the Mechanisms Responsible for Synthetic Lethality in MYC-induced Tumorigenesis Driven by Control of Protein Synthesis$334,015
R01 · FY2019 · CA · contact PI
MYCN, mTOR and translation control in medulloblastoma$596,770
R01 · FY2018 · NS
Deciphering the role of the translational oncogenic program in Prostate Cancer$419,022
R01 · FY2018 · CA · contact PI
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer$359,006
R01 · FY2018 · CA · contact PI
Delineating the Mechanisms Responsible for Synthetic Lethality in MYC-induced Tumorigenesis Driven by Control of Protein Synthesis$347,418
R01 · FY2018 · CA · contact PI
X-linked Dyskeratosis Congenita and ribosomal frameshifting$771,094
R01 · FY2017 · HL
MYCN, mTOR and translation control in medulloblastoma$603,492
R01 · FY2017 · NS
Deciphering the role of the translational oncogenic program in Prostate Cancer$419,077
R01 · FY2017 · CA · contact PI
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer$366,826
R01 · FY2017 · CA · contact PI
Delineating the Mechanisms Responsible for Synthetic Lethality in MYC-induced Tumorigenesis Driven by Control of Protein Synthesis$350,745
R01 · FY2017 · CA · contact PI
X-linked Dyskeratosis Congenita and ribosomal frameshifting$626,694
R01 · FY2016 · HL
MYCN, mTOR and translation control in medulloblastoma$614,079
R01 · FY2016 · NS
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer$374,330
R01 · FY2016 · CA · contact PI
Delineating the Mechanisms Responsible for Synthetic Lethality in MYC-induced Tumorigenesis Driven by Control of Protein Synthesis$352,975
R01 · FY2016 · CA · contact PI
X-linked Dyskeratosis Congenita and Ribosomal Frameshifting$112,100
R01 · FY2016 · HL
MYCN, mTOR and translation control in medulloblastoma$623,844
R01 · FY2015 · NS
X-linked Dyskeratosis Congenita and ribosomal frameshifting$617,294
R01 · FY2015 · HL
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer$381,395
R01 · FY2015 · CA · contact PI
Delineating the Mechanisms Responsible for Synthetic Lethality in MYC-induced Tumorigenesis Driven by Control of Protein Synthesis$356,438
R01 · FY2015 · CA · contact PI
Pharmcogenomic dissection of mTOR translational targets in prostate cancer$353,114
R01 · FY2015 · CA · contact PI
Role of ribosome impairments in X-linked Dyskeratosis Congenita pathogenesis$332,928
R01 · FY2015 · DK · contact PI
Diversity Supplement for MYCN, mTOR and translation control in medulloblastoma$18,214
R01 · FY2015 · NS
X-linked Dyskeratosis Congenita and ribosomal frameshifting$633,014
R01 · FY2014 · HL
MYCN, mTOR and translation control in medulloblastoma$632,206
R01 · FY2014 · NS
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer$386,368
R01 · FY2014 · CA · contact PI
Role of ribosome impairments in X-linked Dyskeratosis Congenita pathogenesis$348,576
R01 · FY2014 · DK · contact PI
Pharmcogenomic dissection of mTOR translational targets in prostate cancer$344,062
R01 · FY2014 · CA · contact PI
Role of ribosome impairments in X-linked Dyskeratosis Congenita pathogenesis$16,533
R01 · FY2014 · DK · contact PI
Pharmcogenomic dissection of mTOR translational targets in prostate cancer$409,727
R01 · FY2013 · CA · contact PI
The role of deregulated protein synthesis control in Myc-induced tumorigenesis$292,312
R01 · FY2013 · CA · contact PI
Role of ribosome impairments in X-linked Dyskeratosis Congenita pathogenesis$270,607
R01 · FY2013 · DK · contact PI
Pharmcogenomic dissection of mTOR translational targets in prostate cancer$430,445
R01 · FY2012 · CA · contact PI
The role of deregulated protein synthesis control in Myc-induced tumorigenesis$310,970
R01 · FY2012 · CA · contact PI
Role of ribosome impairments in X-linked Dyskeratosis Congenita pathogenesis$279,585
R01 · FY2012 · DK · contact PI
Pharmcogenomic dissection of mTOR translational targets in prostate cancer$386,369
R01 · FY2011 · CA · contact PI
The role of deregulated protein synthesis control in Myc-induced tumorigenesis$310,970
R01 · FY2011 · CA · contact PI
RIBOSOMAL RNA SEQUENCE ANALYSIS$11,895
P41 · FY2011 · RR · contact PI
The role of deregulated protein synthesis control in Myc-induced tumorigenesis$320,588
R01 · FY2010 · CA · contact PI
Role of rRNA Modifications in Dyskeratosis Congenita and Translation Control$375,049
R01 · FY2009 · HL · contact PI
The role of deregulated protein synthesis control in Myc-induced tumorigenesis$312,955
R01 · FY2009 · CA · contact PI
Role of rRNA Modifications in Dyskeratosis Congenita and Translation Control$238,616
R01 · FY2009 · HL · contact PI
Role of rRNA Modifications in Dyskeratosis Congenita and Translation Control$375,049
R01 · FY2008 · HL · contact PI
Role of rRNA Modifications in Dyskeratosis Congenita and Translation Control$373,835
R01 · FY2007 · HL · contact PI
Role of rRNA Modifications in Dyskeratosis Congenita and Translation Control$1
R01 · FY2007 · HL · contact PI
Role of rRNA Modifications in Dyskeratosis Congenita$427,500
R01 · FY2006 · HL · contact PI